Table 2.

Cox regression analysis for different maintenance treatment modalities

Group	N	mPFS, months	Univariate analysis		Multivariate analysis*
			HR (95% CI)	p value	HR (95% CI)	p value
Capecitabine	21	7.3	1.0 (ref)		1.0 (ref)
Cetuximab + capecitabine	18	9.5	0.4 (0.2–1.0)	0.039	0.4 (0.1–1.0)	0.041

HR, hazard ratio; CI, confidence interval.

*In multivariate analysis, the controlled covariates included gender, age, primary tumor site, PS score, whether the primary tumor was resected, metastatic time, pathological differentiation, baseline CEA level, MSI status, tumor metastatic site, number of metastatic sites, number of induction treatment cycles, and best response to induction treatment.